Ikena Oncology Stock Forward View
| IKNADelisted Stock | USD 17.16 0.60 3.62% |
Ikena Stock outlook is based on your current time horizon. Investors can use this forecasting interface to forecast Ikena Oncology stock prices and determine the direction of Ikena Oncology's future trends based on various well-known forecasting models. We suggest always using this module together with an analysis of Ikena Oncology's historical fundamentals, such as revenue growth or operating cash flow patterns.
At this time, The value of RSI of Ikena Oncology's share price is at 56. This usually indicates that the stock is in nutural position, most likellhy at or near its resistance level. The main idea of RSI analysis is to track how fast people are buying or selling Ikena Oncology, making its price go up or down. Momentum 56
Buy Extended
Oversold | Overbought |
Using Ikena Oncology hype-based prediction, you can estimate the value of Ikena Oncology from the perspective of Ikena Oncology response to recently generated media hype and the effects of current headlines on its competitors.
The Naive Prediction forecasted value of Ikena Oncology on the next trading day is expected to be 17.42 with a mean absolute deviation of 0.45 and the sum of the absolute errors of 27.57. Ikena Oncology after-hype prediction price | USD 17.16 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as delisted stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Ikena |
Ikena Oncology Additional Predictive Modules
Most predictive techniques to examine Ikena price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Ikena using various technical indicators. When you analyze Ikena charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Ikena Oncology Naive Prediction Price Forecast For the 3rd of February
Given 90 days horizon, the Naive Prediction forecasted value of Ikena Oncology on the next trading day is expected to be 17.42 with a mean absolute deviation of 0.45, mean absolute percentage error of 0.31, and the sum of the absolute errors of 27.57.Please note that although there have been many attempts to predict Ikena Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Ikena Oncology's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Ikena Oncology Stock Forecast Pattern
| Backtest Ikena Oncology | Ikena Oncology Price Prediction | Research Analysis |
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of Ikena Oncology stock data series using in forecasting. Note that when a statistical model is used to represent Ikena Oncology stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 116.9367 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.452 |
| MAPE | Mean absolute percentage error | 0.0291 |
| SAE | Sum of the absolute errors | 27.5729 |
Predictive Modules for Ikena Oncology
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Ikena Oncology. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Ikena Oncology After-Hype Price Density Analysis
As far as predicting the price of Ikena Oncology at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Ikena Oncology or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Ikena Oncology, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Ikena Oncology Estimiated After-Hype Price Volatility
In the context of predicting Ikena Oncology's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Ikena Oncology's historical news coverage. Ikena Oncology's after-hype downside and upside margins for the prediction period are 17.16 and 17.16, respectively. We have considered Ikena Oncology's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Ikena Oncology is very steady at this time. Analysis and calculation of next after-hype price of Ikena Oncology is based on 3 months time horizon.
Ikena Oncology Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Ikena Oncology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ikena Oncology backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Delisted Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Ikena Oncology, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.00 | 0.00 | 0.00 | 0.00 | 4 Events / Month | 4 Events / Month | In about 4 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
17.16 | 17.16 | 0.00 |
|
Ikena Oncology Hype Timeline
Ikena Oncology is currently traded for 17.16. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Ikena is estimated not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is estimated to be very small, whereas the daily expected return is currently at 0.0%. %. The volatility of related hype on Ikena Oncology is about 0.0%, with the expected price after the next announcement by competition of 17.16. About 76.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 7.68. Ikena Oncology had not issued any dividends in recent years. The entity had 1:12 split on the 28th of July 2025. Given the investment horizon of 90 days the next estimated press release will be in about 4 days. Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.Ikena Oncology Related Hype Analysis
Having access to credible news sources related to Ikena Oncology's direct competition is more important than ever and may enhance your ability to predict Ikena Oncology's future price movements. Getting to know how Ikena Oncology's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Ikena Oncology may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| ASLN | Aslan Pharmaceuticals | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EXAI | Exscientia Ltd ADR | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| ICVX | Icosavax | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| CDMO | Avid Bioservices | 0.01 | 8 per month | 0.00 | 0.16 | 1.93 | (0.57) | 13.69 | |
| CMRX | Chimerix | 0.01 | 9 per month | 1.23 | 0.18 | 8.17 | (3.95) | 70.92 | |
| SAGE | Sage Therapeutics | 0.06 | 8 per month | 1.70 | 0.04 | 3.61 | (3.48) | 37.83 | |
| ICPT | Intercept Pharmaceuticals | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| IVVD | Invivyd | (0.01) | 10 per month | 0.00 | (0.01) | 11.11 | (9.43) | 46.37 | |
| ITOS | Iteos Therapeutics | (0.01) | 6 per month | 0.43 | (0.07) | 1.09 | (0.79) | 3.17 | |
| NAGE | Niagen Bioscience | 0.02 | 6 per month | 0.00 | (0.13) | 3.66 | (4.05) | 10.35 |
Ikena Oncology Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Ikena Oncology stock to make a market-neutral strategy. Peer analysis of Ikena Oncology could also be used in its relative valuation, which is a method of valuing Ikena Oncology by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Ikena Oncology Market Strength Events
Market strength indicators help investors to evaluate how Ikena Oncology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Ikena Oncology shares will generate the highest return on investment. By undertsting and applying Ikena Oncology stock market strength indicators, traders can identify Ikena Oncology entry and exit signals to maximize returns.
Ikena Oncology Risk Indicators
The analysis of Ikena Oncology's basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Ikena Oncology's investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting ikena stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 2.61 | |||
| Semi Deviation | 2.9 | |||
| Standard Deviation | 3.52 | |||
| Variance | 12.38 | |||
| Downside Variance | 10.56 | |||
| Semi Variance | 8.4 | |||
| Expected Short fall | (3.21) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Ikena Oncology
The number of cover stories for Ikena Oncology depends on current market conditions and Ikena Oncology's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Ikena Oncology is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Ikena Oncology's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Ikena Oncology Short Properties
Ikena Oncology's future price predictability will typically decrease when Ikena Oncology's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Ikena Oncology often depends not only on the future outlook of the potential Ikena Oncology's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Ikena Oncology's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 48.3 M | |
| Cash And Short Term Investments | 124.4 M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Other Consideration for investing in Ikena Stock
If you are still planning to invest in Ikena Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ikena Oncology's history and understand the potential risks before investing.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |